aTyr Pharma, Inc.
ATYR
$0.86
$0.0911.27%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.72% | -15.10% | -17.58% | -27.06% | -47.89% |
| Total Depreciation and Amortization | -40.55% | -54.68% | -58.16% | -43.82% | -35.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,648.77% | 400.49% | 217.86% | 148.21% | -174.65% |
| Change in Net Operating Assets | 270.01% | 207.09% | 69.77% | -146.08% | -168.06% |
| Cash from Operations | 6.16% | 12.37% | -12.99% | -108.06% | -106.13% |
| Capital Expenditure | -24.56% | 91.82% | 98.39% | 98.46% | 98.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -53.33% | -53.33% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -166.80% | -61.72% | -27.72% | 208.56% | 234.42% |
| Cash from Investing | -167.05% | -61.04% | -15.10% | 185.62% | 214.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9.09% | -10.71% | -12.92% | -26.14% | -40.29% |
| Issuance of Common Stock | 210.46% | 84.00% | 105.79% | -39.42% | -55.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 214.06% | 85.15% | 107.50% | -39.81% | -55.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -581.85% | 272.39% | 120.00% | -193.32% | 115.57% |